Category: Psychedelic Bulletin - Page 9 - Psychedelic Alpha

Read more about the article Psychedelic Bulletin #113 – Analysis of Company Spending Trends; Morgan Stanley Opine on Psychedelics; COMPASS Rallies

Psychedelic Bulletin #113 – Analysis of Company Spending Trends; Morgan Stanley Opine on Psychedelics; COMPASS Rallies

Post published:August 6, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #112 – Inside the DEA Challenge; Second Psychedelics Company Enters Death Spiral Financing

Psychedelic Bulletin #112 – Inside the DEA Challenge; Second Psychedelics Company Enters Death Spiral Financing

Post published:July 29, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #111 – Psychedelics on Netflix; House Adopts 2 Psychedelic Research Amendments; Taking the Magic Out of Magic Mushrooms?

Psychedelic Bulletin #111 – Psychedelics on Netflix; House Adopts 2 Psychedelic Research Amendments; Taking the Magic Out of Magic Mushrooms?

Post published:July 15, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #110 – Psychedelics Docuseries Comes to Netflix; DEA Schedules Public Hearing on Banning 5 Psychedelics

Psychedelic Bulletin #110 – Psychedelics Docuseries Comes to Netflix; DEA Schedules Public Hearing on Banning 5 Psychedelics

Post published:July 11, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #109 – California Decrim. Back on the Agenda; Reanalysis of NEJM Psilocybin vs. Escitalopram Trial; Off-Label = Off the Rails?

Psychedelic Bulletin #109 – California Decrim. Back on the Agenda; Reanalysis of NEJM Psilocybin vs. Escitalopram Trial; Off-Label = Off the Rails?

Post published:July 4, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #108 – COMPASS Survives Patent Challenges; MindMed Secures Candyflipping IP; Will Psychedelics Companies Protect Access to Abortion for Employees?

Psychedelic Bulletin #108 – COMPASS Survives Patent Challenges; MindMed Secures Candyflipping IP; Will Psychedelics Companies Protect Access to Abortion for Employees?

Post published:June 27, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #107 – Call for Proposals: Opinions Column; How to Change Your Mind Comes to Netflix

Psychedelic Bulletin #107 – Call for Proposals: Opinions Column; How to Change Your Mind Comes to Netflix

Post published:June 18, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #106 – DMT Study Skips Set and Setting; Cybin Acquires Phase 1 Study; FDA Snubs Seamless Trial Design

Psychedelic Bulletin #106 – DMT Study Skips Set and Setting; Cybin Acquires Phase 1 Study; FDA Snubs Seamless Trial Design

Post published:June 13, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #105 – UK Won’t Foot the Bill for Spravato; Another KAP Provider Launches; Canadian Province Decriminalises Possession of MDMA and Other Drugs

Psychedelic Bulletin #105 – UK Won’t Foot the Bill for Spravato; Another KAP Provider Launches; Canadian Province Decriminalises Possession of MDMA and Other Drugs

Post published:June 3, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #104 – Mydecine CEO Downplays Insider Activity; UC Davis Scores $2.7m to Study Non-hallucinogenic Psychedelics; Oregon Health Authority Adopts Rules

Psychedelic Bulletin #104 – Mydecine CEO Downplays Insider Activity; UC Davis Scores $2.7m to Study Non-hallucinogenic Psychedelics; Oregon Health Authority Adopts Rules

Post published:May 27, 2022
Post category:Psychedelic Bulletin

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.